Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics
Study Details
Study Description
Brief Summary
ALTB-268-201 is a Phase 2a, multicenter, single arm, multiple-dose, open-label study evaluating the efficacy and safety of ALTB-268 in subjects with moderately to severely active UC. The study consists of a Screening Phase, an Induction Phase, and a Maintenance Phase.
Eligible subjects will be enrolled to receive a SC loading dose of ALTB-268 followed by weekly doses of ALTB-268 for 12 weeks. Primary efficacy endpoint will be evaluated at week 12.
Week 12 dosing will occur during the 40 wks Maintenance Phase.
During 40 weeklong maintenance phase SC doses of ALTB-268 will be administered every other week. At week 52, all subjects will have an endoscopy performed and efficacy and safety evaluation will take place.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
ALTB-268-201 is a Phase 2a, multicenter, single arm, multiple-dose, open-label study evaluating the efficacy and safety of ALTB-268 in subjects with moderately to severely active UC.
The study consists of a Screening Phase, an Induction Phase, and a Maintenance Phase. Upon successful completion of the Screening Phase, subjects will return to the clinic for their first visit, which must occur within 28 days of SV1. Eligible subjects will be enrolled to receive a SC loading dose of ALTB-268. followed by a weekly maintenance dose of ALTB-268 in the 12 week Induction Study Phase. During the Induction Phase, study participants will be evaluated weekly at V0 (Day 1), V1 (Week 1), V2 (Week 2), V3 (Week 3), V4 (Week 4), V5 (Week 5), V6 (Week 6), V7 (Week 7), V8(Week 8), V9 (Week 9), V10 (Week 10), and V11 (Week 11) and V12 (Week 12; End of Induction Phase). Participants entering the maintenance study phase will continue to receive the SC dose of ALTB-268 every two weeks, up to week 52. Upon completion of the maintenance study phase, study participants will be asked to return for an end of study visit in approximately 4 weeks, for end of study visit.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: ALTB-268 ALTB-268 IP will be administered via subcutaneous injection. One loading dose will be followed by 10 weekly doses of ALTB-268 in the 12 weeks induction study phase. Additional 20 biweekly doses of ALTB-268 will be administered in the 40 week maintenance study period. |
Biological: ALTB-268
ALTB-268 drug product (DP) for SC injection is supplied as a sterile and preservative-free frozen solution or lyophilized powder. All excipients used in the DP formulation are of multi-compendial quality and have precedence for use in parenteral products.
|
Outcome Measures
Primary Outcome Measures
- Efficacy - change in mMS at week 12 [week 12]
Change from baseline in mMS at Week 12. The modified Mayo score (mMayo Score) is a measure of disease activity in ulcerative colitis. It is based on stool frequency (SF), rectal bleeding (RB), and endoscopic subscore (ES). The mMS ranges from 0 to 9. A lower mMS means less severe UC, and a higher mMS means more severe UC.
Secondary Outcome Measures
- Efficacy - proportion of subjects with clinical response at week 12 and week 52 [week 12 and week 52]
The proportion of subjects with clinical response at Week 12 and Week 52, defined as a decrease from baseline in the mMS of ≥ 2 points AND at least a 30% reduction from the baseline score, AND a decrease in the RB subscore of ≥ 1 point or an absolute RB score of 0 or 1. The modified Mayo score (mMayo) is a measure of disease activity in UC. It is based on stool frequency (SF), rectal bleeding (RB), and endoscopic subscore (ES). The mMS ranges from 0 to 9. A lower mMS means less severe UC, and a higher mMS means more severe UC.
- Efficacy - proportion of subjects with clinical remission at week 12 and week 52 [week 12 and week 52]
The proportion of subjects with clinical remission at Week 12 and Week 52, defined as mMS of ≤ 2 points, with a SF subscore of ≤ 1 point, a RB subscore of 0, and an endoscopic subscore of ≤ 1 point. The modified Mayo score (mMayo) is a measure of disease activity in ulcerative colitis. It is based on stool frequency (SF), rectal bleeding (RB), and endoscopic subscore (ES). The mMS ranges from 0 to 9. A lower mMS means less severe UC, and a higher mMS means more severe UC. A mMS of 0 or 1 means remission.
- Efficacy - proportion of subjects with endoscopic improvement at week 12 and week 52 [week 12 and week 52]
The proportion of subjects with endoscopic improvement, defined as a centrally read endoscopy score of ≤1 at Week 12 and Week 52. Endoscopic subscore 0-3: 0 (normal of inactive disease), 1 mild disease (erythema, decreased vascular pattern and mild friability); 2 moderate disease (mark erythema, lack of vascular pattern, friability and erosions); 3 sever disease (spontaneous bleeding and ulceration) Lower score means improvement.
- Efficacy -proportion of subjects with endoscopic remission at week 12 and week 52 [week 12 and week 52]
The proportion of subjects with endoscopic remission, defined as a centrally read endoscopy score of 0 at Week 12 and Week 52 Endoscopic subscore 0-3: 0 (normal of inactive disease), 1 mild disease (erythema, decreased vascular pattern and mild friability); 2 moderate disease (mark erythema, lack of vascular pattern, friability and erosions); 3 sever disease (spontaneous bleeding and ulceration) Lower score means improvement. Endoscopic score 0 indicates remission.
- Efficacy - histological remission, defined as a Robarts Histopathology Index (RHI) [week 12 and week 52]
Histological remission, defined as a Robarts Histopathology Index (RHI) Score of ≤ 3 at Week 12 and Week 52 . Robarts Histopathology Index (RHI) measures histological disease activity in ulcerative colitis. RHI ranges from 0-12, with higher score indicating more active disease. Histological remission corresponds with the score 3 or less.
- Efficacy- change from baseline in RHI score at Week 12 and Week 52 [week 12 and week 52]
Change from baseline in RHI score at Week 12 and Week 52 Histological remission, defined as a Robarts Histopathology Index (RHI) Score of ≤ 3 at Week 12 and Week 52 Robarts Histopathology Index (RHI) measures histological disease activity in ulcerative colitis. RHI ranges from 0-12, with higher score indicating more active disease. Histological remission corresponds with the score 3 or less. The lower score means improvement.
- Efficacy - Histological remission, defined as a Geboes score of ≤ 2 [week 12 and week 52]
Histological remission, defined as a Geboes score of ≤ 2 at Week 12 and Week 52. The original Geboes grade system is from Grade 0 to Grade 5. The following are the grades: Grade 0: Architectural changes Grade 1: Chronic inflammatory infiltrate Grade 2A: Eosinophils in lamina propria Grade 2B: Neutrophils in lamina propria Grade 3: Neutrophils in epithelium Grade 4:Crypt destruction Grade 5: Erosions and ulcerations The lower score means improvement.
- Efficacy -Change from baseline in mMS [week 52]
Change from baseline in mMS at Week 52 The modified Mayo score (mMayo Score) is a measure of disease activity in ulcerative colitis. It is based on stool frequency (SF), rectal bleeding (RB), and endoscopic subscore (ES). The mMS ranges from 0 to 9. A lower mMS means less severe UC, and a higher mMS means more severe UC.
- Efficacy - proportion of subjects with corticosteroid free clinical remission [week 52]
The proportion of subjects with corticosteroid-free clinical remission at Week 52 in subjects receiving corticosteroids on the first day of dosing and electing to undergo corticosteroid tapering during the Maintenance Phase
- Efficacy - proportion of subjects with corticosteroid free clinical response [week 52]
The proportion of subjects with corticosteroid-free clinical response at Week 52 in subjects receiving corticosteroids on the first day of dosing and electing to undergo corticosteroid tapering during the maintenance phase.
- Efficacy - change in mMS [week 12 and week 52]
Change in individual mMS subscores The modified Mayo score (mMayo Score) is a measure of disease activity in ulcerative colitis. It is based on stool frequency (SF), rectal bleeding (RB), and endoscopic subscore (ES). The mMS ranges from 0 to 9. A lower mMS means less severe UC, and a higher mMS means more severe UC.
- Efficacy - change in IBDQ score [week 12 and week 52]
15. Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) score at Week 12 and Week 52 The IBDQ is a questionnaire used for an assessment of Health Related Quality of Life (HRQoL) in patients with the Inflammatory Bowel Disease (IBD). The IBDQ has a possible score range of 32 (minimum) to 224 (maximum), where a higher score indicates better HRQoL. The outcome measure is assessed by comparing each patient's change in individual IBDQ score from Baseline to Week 12, and from Baseline to Week 52.
Other Outcome Measures
- Immunogenicity [week 12 and week 52]
Immunogenicity (Anti Drug Antibody - ADA) of ALTB-268 will be evaluated by a qualitative bridging immunoassay with electrochemiluminescence detection
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Adult participants 18 to 75 years old, inclusive, at Screening.
-
Willing to provide informed consent and to be compliant with the schedule of study visits and protocol assessments.
-
Diagnosis of UC established at least 12 weeks prior to Screening by standard clinical and endoscopic evidence and corroborated by a histopathology report.
-
Moderately to severely active UC, at the time of Screening, defined as a modified Mayo Score (mMS) of 4-9, inclusive, with an endoscopic subscore of ≥ 2 (from central reading), and a rectal bleeding (RB) subscore of ≥ 1.
-
Evidence of active UC, extending proximal to the rectum with ≥ 15 cm of involved colon.
-
Stable doses of concomitant medications:
-
Previous treatment with at least one biologic therapy that demonstrated an inadequate response and/or loss of response.
-
Negative pregnancy test during Screening and Day 1 (V0) in females of childbearing potential.
-
Females with reproductive potential must be sexually abstinent or be willing to use a highly effective method of contraception from study start to
≥ 3 months after the final dose of the study drug. Highly effective methods of contraception include:
-
Male subjects must be either surgically sterile (must have documented proof), agree to be sexually abstinent, or use a double-barrier method of birth control (e.g., condom and diaphragm with spermicide, condom with cervical cap and spermicide) from first study drug administration to ≥ 3 months after the final dose administration.
-
Male subjects must agree to refrain from donating sperm from first study drug administration to ≥ 3 months after final dose administration.
Exclusion Criteria:
-
Diagnosis of Crohn's colitis, colitis yet to be classified, ischemic colitis, nonsteroidal anti-inflammatory drug (NSAID)-induced colitis, idiopathic colitis (i.e., colitis not consistent with UC), or radiation-induced colitis.
-
Ulcerative colitis limited to the rectum (ulcerative proctitis).
-
Presence of short bowel syndrome.
-
History of colectomy, or presence of an ileostomy or colostomy.
-
History of, or active colonic mucosal dysplasia.
-
Treatment with any intravenous (IV) corticosteroid or rectal therapy during the Screening period.
-
Treatment with any calcineurin inhibitor (e.g., cyclosporine, tacrolimus) within 4 weeks prior to Screening.
-
Treatment with NSAIDs within 4 weeks prior to Screening. Short-term use (<7 days) of NSAIDs for non-UC related symptoms is allowed.
-
Treatment with tofacitinib or other Janus Kinase (JAK) inhibitors within 4 weeks prior to Screening.
-
Treatment with sphingosine-1-phosphate receptor (S1PR) modulators within 4 weeks prior to Screening.
-
Biologic therapy within 56 days or 5 half-lives (whichever is longer) prior to Screening. Confirmation of undetectable or non-therapeutic serum levels, as assessed by the Investigator, will allow for eligibility.
-
Tube feeding, defined formula diets, or parenteral alimentation/nutrition within 3 weeks of first dosing.
-
Treatment with oral antibiotics within 4 weeks prior to Screening or IV antibiotics within 8 weeks prior to Screening.
-
Vaccination with a live or live-attenuated vaccine within 4 weeks prior to Screening.
-
History of dysplasia or malignancy in the past 5 years, except completely excised basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
-
Subjects with a current or recent history of severe, progressive, or uncontrolled cardiac (including uncontrolled hypertension), renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac, or neurological (e.g., history of seizures) disease, or any other severe comorbidity that, in the opinion of the Investigator, could confound the study results or put the subject at unreasonable risk.
-
Significant screening electrocardiogram (ECG) abnormalities, including evidence of acute myocardial infarction, complete left bundle branch block, second-degree heart block, or complete heart block.
-
For males, a QTc interval (Fridericia's correction) of >450 ms, and for females, a QTc interval (Fridericia's correction) of >470 ms.
-
Laboratory abnormalities during the Screening period as listed in the study protocol
-
Human immune deficiency virus (HIV) infection or known HIV-related malignancy.
-
Acute or chronic hepatitis B (HBV) or hepatitis C (HCV), or carrier status. Subjects with anti-HBc (hepatitis B core) antibodies (Ab) but with undetectable anti-HBs (hepatitis B surface) Ab should be excluded.
-
Positive immunoglobulin M (IgM) Ab titers in the presence of negative immunoglobulin G (IgG) Ab titers to Epstein-Barr virus (EBV).
-
Positive stool test for ova or parasites, positive stool culture for pathogens, or positive stool toxin assay for Clostridium difficile at Screening.
-
Active cytomegalovirus (CMV) infection at Screening, as assessed by the Investigator.
-
Positive QuantiFERON® TB test at Screening for latent Mycobacterium tuberculosis (TB) infection. If a QuantiFERON® TB test is indeterminate, the test should be repeated.
-
History of any opportunistic infection within 12 weeks of first dosing.
-
Any current or recent symptoms/signs of infection, except nasopharyngitis, within 4 weeks of first dosing.
-
Cirrhosis or active alcohol abuse, per the judgment of the Investigator.
-
History of drug abuse according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) criteria within 12 months prior to Screening or a positive drug screening test.
-
Currently breast feeding, or pregnant.
-
Known hypersensitivity or intolerance to ALTB-268 or any of its excipients.
-
Participation in another clinical trial AND having received investigational medication within 30 days or 5 half-lives (whichever is longer) prior to Screening or having used an investigational device treatment within 30 days prior to Screening. Concurrent participation in an observational or long-term
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Gastro Associates of Florida / GI Alliance | Wellington | Florida | United States | 33141 |
| 2 | DHAT / GI Aliance | Garland | Texas | United States | 75044 |
| 3 | Caprock Gastro Reasearch | Lubbock | Texas | United States | 19424 |
| 4 | GI Alliance | Mansfield | Texas | United States | 760603 |
| 5 | Southern Star Research Institute LLC | San Antonio | Texas | United States | 78229 |
| 6 | Tyler Research Institute | Tyler | Texas | United States | 75701 |
| 7 | GI Alliance | Webster | Texas | United States | 33016 |
Sponsors and Collaborators
- AltruBio Inc.
Investigators
- Study Director: Jesse Hall, MD, AltruBio Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AltruBio, Inc.